DRI Healthcare Trust (DHT-UN) Q2 2024 earnings summary

Executive summary

• Leadership changes followed an internal investigation into expense irregularities, resulting in new executive appointments and a focus on governance and internal controls.

• The Trust restated its 2022 and 2023 financials and is actively remediating material weaknesses in internal controls.

• Business performance remained strong, with robust execution on strategy, continued capital deployment, and a record $43.0 million in normalized total cash receipts in Q2 2024.

• Focus on deal execution, capital allocation, and unitholder returns, supported by a robust pipeline of over $3.2 billion in potential opportunities.

Financial highlights

• Q2 2024 normalized total cash receipts were $43.0 million, up 50% year-over-year.

• Total income reached $41.6 million, a 48% increase from Q2 2023.

• Adjusted EBITDA was $32.9 million, up 31% year-over-year, with a margin of 77%.

• Adjusted cash earnings per unit were $0.49 for Q2 2024 and $2.47 for the last twelve months.

• Cash and equivalents stood at $53.9 million, with $260.8 million in available credit as of June 30, 2024.

Outlook and guidance

• 2024 royalty income guidance (excluding milestones and new transactions): $153–$155 million, up from $117.5 million in 2023 on a comparable basis.

• High teens royalty income CAGR expected through 2025; mid to high single-digit CAGR through 2030.

• Portfolio duration extended to over 10 years, in line with 2025 targets and supported by equity offerings and credit facilities.

• Increased five-year capital deployment target to over $1.25 billion, up from the original $650–$750 million.

• No need to raise additional equity to meet deployment targets.